Advertisement

Featured in NEJM Journal Watch: Dupilumab for Atopic Dermatitis; Secukinumab for Plaque Psoriasis — Physician’s First Watch

Medical News |
July 10, 2014

Featured in NEJM Journal Watch: Dupilumab for Atopic Dermatitis; Secukinumab for Plaque Psoriasis

By the NEJM Journal Watch Editors

This week, NEJM Journal Watch Dermatology summarizes two reports from the New England Journal of Medicine on treatment with fully human monoclonal antibodies.

In the first, investigators conducted four multicenter, randomized, double-blind, placebo-controlled clinical trials to evaluate treatment of moderate-to-severe atopic dermatitis with dupilumab, which inhibits both interleukin (IL)-4 and IL-13. Patients in the treatment group saw significant improvements in eczema severity and pruritus.

In the second, two studies of patients with plaque psoriasis found that injectable secukinumab, which selectively binds and neutralizes IL-17A, was more efficacious than etanercept or placebo for all endpoints.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement